MedPath

Health Canada Approves Moderna's mRNA-Based RSV Vaccine, mRESVIA

  • Health Canada has approved Moderna's mRESVIA vaccine for active immunization against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 60 and older.
  • This approval marks the second Health Canada approval for Moderna, highlighting the potential of its mRNA platform to address significant public health challenges.
  • mRESVIA generated $10 million in sales during its first quarter of commercialization, having already gained approval in the US and Europe earlier this year.
Moderna's mRESVIA, a respiratory syncytial virus (RSV) mRNA vaccine, has received approval from Health Canada for active immunization in adults 60 years and older, designed to prevent lower respiratory tract disease caused by RSV. This approval follows the vaccine's earlier authorization in the United States and Europe, marking a significant milestone for Moderna's mRNA platform.
The approval underscores the potential of mRNA technology in addressing public health challenges. According to Moderna CEO Stéphane Bancel, this approval highlights the company's commitment to leveraging mRNA technology to protect vulnerable populations and contribute to a healthier future for Canadians.
mRESVIA generated $10 million in sales in its first quarter of commercialization, indicating a strong initial uptake following its launch in other markets. The vaccine aims to address the significant burden of RSV-related lower respiratory tract disease in older adults, a population particularly vulnerable to severe outcomes.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Moderna's mResvia RSV Vaccine for Older Adults

- The FDA has approved Moderna's mResvia (mRNA-1345), an mRNA vaccine, for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and over.
- mResvia demonstrated 78.7% efficacy against RSV with two or more symptoms at 3.7 months, decreasing to 62.5% at 8.6 months follow-up in clinical trials.

FDA Approves Abrysvo for RSV Prevention in Adults Aged 18-59 at Increased Risk

- The FDA has approved Abrysvo, Pfizer's RSV vaccine, for adults aged 18-59 at increased risk of RSV-associated lower respiratory tract disease.
- Abrysvo is the first RSV vaccine approved for adults younger than 50, addressing a crucial need for at-risk individuals in this age group.

FDA Panel Urges Caution and More Data on RSV Vaccine Safety in Infants

- An FDA advisory panel called for more safety data on RSV vaccines for infants, highlighting concerns after a partial pause in clinical trials.
- The pause was triggered by cases of severe RSV in infants receiving Moderna's experimental vaccines, raising questions about vaccine-associated enhanced respiratory disease (VAERD).

Health Canada Approves Moderna's mRNA RSV Vaccine for Older Adults

- Health Canada has approved Moderna's mRNA-based vaccine for respiratory syncytial virus (RSV) in adults aged 60 years and older, marking a significant step in preventative medicine.
- The approval is based on clinical trial data demonstrating the vaccine's efficacy in reducing the risk of RSV-associated lower respiratory tract disease in the target population.

Health Canada Approves Moderna's mRNA RSV Vaccine mRESVIA

- Health Canada has approved Moderna's mRESVIA, the first mRNA vaccine for respiratory syncytial virus (RSV) in Canada, targeting adults aged 60 and over.
- The approval was based on the Phase III ConquerRSV trial, which demonstrated an 83.7% efficacy in preventing RSV-related lower respiratory tract disease (LRTD).

RSV Vaccines and Monoclonal Antibodies: A Year in Review

- FDA approved Moderna's mRNA-1345 (mResvia) for adults 60+ and expanded approvals for GSK's Arexvy and Pfizer's Abrysvo to include younger at-risk adults.
- ACIP updated RSV vaccination recommendations, advising a single dose for adults 75+ and considering it for those 60-74 at increased risk.

GSK's RSV Vaccine AREXVY Approved in Canada for Adults Aged 50-59

- GSK's AREXVY vaccine has been approved in Canada for adults aged 50-59 at increased risk of lower respiratory tract disease (LRTD) caused by RSV.
- The approval is based on positive Phase III trial outcomes, which demonstrated the vaccine's immunogenicity and safety in the specified age group with underlying conditions.

Moderna's Updated COVID-19 Vaccine Targeting JN.1 Receives Positive CHMP Opinion

- Moderna's updated Spikevax vaccine, targeting the SARS-CoV-2 variant JN.1, has received a positive recommendation from the EMA's CHMP.
- The vaccine is intended for active immunization against COVID-19 in individuals aged six months and older, aligning with EMA guidance.

FDA Approves Moderna's mResvia, Third RSV Vaccine for Older Adults

- The FDA has approved Moderna's mResvia vaccine for the prevention of RSV in adults aged 60 and older, making it the third approved RSV vaccine.
- mResvia, like Moderna's COVID-19 vaccine, utilizes mRNA technology to target the prefusion F protein of RSV, offering a prefilled syringe for easier administration.

FDA Approves First RSV Vaccine, Arexvy, for Older Adults

- The FDA has approved Arexvy, the first vaccine against respiratory syncytial virus (RSV), for adults aged 60 and older, marking a significant public health advancement.
- Clinical trials demonstrated Arexvy's high efficacy, reducing the risk of lower respiratory tract illness by 83% and severe disease by 94% in the target population.

Reference News

[1]
Health Canada approval for Moderna's RSV vaccine | Biotechnology | The Pharmaletter
thepharmaletter.com · Nov 9, 2024

Moderna announces Health Canada approval of mRESVIA, an mRNA vaccine for preventing RSV-related lower respiratory tract ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy